Xtant Medical (XTNT) Projected to Release Quarterly Earnings on Tuesday

Xtant Medical (NYSEAMERICAN:XTNT) is projected to announce its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect the company to post earnings of ($0.0250) per share and revenue of $25.48 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:30 AM ET.

Xtant Medical (NYSEAMERICAN:XTNT) last issued its quarterly earnings results on Tuesday, August 11th. The medical device company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.05). The company had revenue of $23.03 million for the quarter, compared to analyst estimates of $24.88 million. Xtant Medical had a negative net margin of 10.17% and a negative return on equity of 23.45%.

Xtant Medical Stock Up 2.3%

Shares of NYSEAMERICAN:XTNT traded up $0.01 during trading on Tuesday, hitting $0.28. 24,828 shares of the company were exchanged, compared to its average volume of 610,924. The stock has a market cap of $39.95 million, a price-to-earnings ratio of -3.56 and a beta of -0.20. Xtant Medical has a fifty-two week low of $0.27 and a fifty-two week high of $0.85. The firm has a fifty day moving average price of $0.33 and a two-hundred day moving average price of $0.46. The company has a current ratio of 2.16, a quick ratio of 1.05 and a debt-to-equity ratio of 0.18.

Analysts Set New Price Targets

Separately, Loop Capital set a $1.00 price objective on Xtant Medical in a report on Wednesday, September 2nd. Two research analysts have rated the stock with a Buy rating. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $1.00.

About Xtant Medical

Xtant Medical Holdings, Inc is a medical technology company focused on developing, manufacturing and distributing orthobiologic and spinal implant products. Its offerings are designed to support bone growth, spinal fusion and the repair or reconstruction of musculoskeletal tissue.

The company’s product portfolio includes biologic materials such as allograft and other regenerative tissue products, along with spinal implants, interbody devices, fixation systems and related surgical instruments.